Why Biotechnology Company Carmell Shares Are Rocketing On Thursday
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 02 2025
0mins
Source: Benzinga
Acquisition Details: Carmell Corporation has entered a definitive purchase agreement with PMGC Holdings Inc. for approximately $1.1 million in stock and $57,000 in cash, along with contingent earnout considerations based on Elevai's net sales over the next five years.
Financial Impact: The acquisition is expected to enhance Carmell's product portfolio, which includes assets valued at around $2.5 million in revenue and inventory worth about $1.0 million, while their stock price surged by 215.8% following the announcement.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
